Dental Membrane and Bone Graft Substitutes Market to Expand at ~9% CAGR and ~$1.565M in Size

Dental Membrane and Bone Graft Substitutes Market to Expand at ~9% CAGR and ~.565M in Size

The dental membrane and bone graft substitute market is estimated to achieve revenue of USD 1.565 billion by the end of 2033 growing at a CAGR of ~9% by 2033. NEW YORK, UNITED STATES, December 22, 2022 /EINPresswire.com/ — Global Dental Membrane and Bone Graft Substitutes Key Market Insights During the forecast period of 2023~2033, … Read more

BioRestorative Therapies Announces SBIR Phase I Grant to Explore Therapeutic Effects of ThermoStem Targeting Polycystic Ovarian Syndrome As an Indication

BioRestorative Therapies Announces SBIR Phase I Grant to Explore Therapeutic Effects of ThermoStem Targeting Polycystic Ovarian Syndrome As an Indication

BioRestorative Therapies, Inc. (‘BioRestorative’, ‘BRTX’ or the ‘Company’) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, announced today that it has received a Innovation Research for Small Businesses (SBIR) Grant Phase I of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of National Institutes of Health. This collaborative research … Read more

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100 Disc Program to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100 Disc Program to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. (‘BioRestorative’ or the ‘Company’) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to treat chronic lumbar disc disease have become exclusive. The intellectual property now exclusively licensed … Read more

DKSH: Lupine and DKSH sign an exclusive license and supply agreement to commercialize five biosimilars in the Philippines

DKSH: Lupine and DKSH sign an exclusive license and supply agreement to commercialize five biosimilars in the Philippines

Press release Lupine and DKSH sign an exclusive license and supply agreement to commercialize five biosimilars in the Philippines DKSH and Lupine have signed an exclusive license and supply agreement to commercialize five of Alvotech’s high-quality biosimilars in the Philippines. Philippines, August 25, 2022 – DKSH Business Unit Healthcare, a leading partner … Read more

Adaptive Biotechnologies announces the launch of clonoSEQ® to assess minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA)

Adaptive Biotechnologies announces the launch of clonoSEQ® to assess minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA)

clonoSEQ is the first and only Medicare-covered DLBCL MRD test across all lines of therapy, treatment regimens, and time points Adaptive now accepts blood samples from DLBCL patients in ctDNA-stabilizing Streck® tubes SEATTLE, December 01, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of … Read more

JBM Healthcare Announces Interim Results for Fiscal Year 2023

JBM Healthcare Announces Interim Results for Fiscal Year 2023

HONG KONG, November 25, 2022 – (ACN Newswire) – – JBM (medical care) limited (“JBM Health” or the “Group”; Stock Code: 2161), a leading marketer and distributor of brand name healthcare products in Hong Kongtoday announced the Group’s intermediate results for the semester ended September 30, 2022 (the “Reporting Period”). KEY POINTS — Period-over-period revenue … Read more

Innovative treatment for chemotherapy hair loss will be presented at Stora Aktiedagen

Innovative treatment for chemotherapy hair loss will be presented at Stora Aktiedagen

dignitana CEO Catarina Mård Löwenadler will speak at Aktiespararna Stora Aktiedagen on November 29 in Stockholm. Ms. Löwenadler’s 20-minute presentation begins at 1830 CE and it will be broadcast live. Event participants will have the opportunity to ask questions after your presentation. “Increased demand and high customer satisfaction continue to drive of dignitana increase. We … Read more

BioSenic – Transparency notifications received from Francois Rieger, Veronique Pomi, Capital Grand Est FA DIESE 3 and CPH Banque

BioSenic – Transparency notifications received from Francois Rieger, Veronique Pomi, Capital Grand Est FA DIESE 3 and CPH Banque

BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in the areas of innate immunity, inflammation and function/organ repair, announces today that it has received transparency notifications from François Rieger, veronique pomiGreat East of the capital, FA DIES 3 and CPH Bank. Details of the notices are below and can be … Read more

Asep Medical Holdings Inc. announces listing of its ordinary shares on the Frankfurt Stock Exchange

Asep Medical Holdings Inc. announces listing of its ordinary shares on the Frankfurt Stock Exchange

VANCOUVER, BC, November 21, 2022 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: FSX: JJ8) is pleased to announce that its ordinary shares began trading on the Frankfurt Stock Exchange (FSE) on November 10, 2022under the ticker symbol FSX: JJ8. The Company’s common shares will continue to … Read more

Egetis continues to strengthen commercial and medical affairs organizations for the expected launch of Emcitate® in 2024

Egetis continues to strengthen commercial and medical affairs organizations for the expected launch of Emcitate® in 2024

Stockholm, Switzerland, November 18, 2022. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced more key hires for its commercial and medical affairs organizations in the United States Y Europein preparation for the highly anticipated launch of Egetis’ lead drug candidate excite in 2024. These key recruits bring substantial experience and proven track records in … Read more